Multisystem Processes & Disorders

Bacteremia and central line-associated bloodstream infection

Clinical Overview and When to Suspect Bacteremia/CLABSI

— New fever (>38.0°C) or hypothermia in a patient with indwelling vascular access

— Unexplained sepsis physiology: tachycardia, hypotension, altered mentation, lactate elevation

— Rigors temporally linked to line flushing or dialysis runs (highly specific)

— New organ dysfunction (AKI, thrombocytopenia, hyperbilirubinemia) without alternative source

— Persistent fever after appropriate antibiotics for a presumed alternative source

— CLABSI rate is a publicly reported CMS quality metric tied to value-based purchasing

— Femoral > internal jugular > subclavian for infection risk (subclavian preferred when feasible)

— Most CLABSIs arise from extraluminal skin organisms migrating along the catheter tract in the first 7–10 days; intraluminal hub contamination dominates after ~2 weeks

Bacteremia = viable bacteria in the bloodstream documented by blood culture; CLABSI (CDC/NHSN definition) = laboratory-confirmed bloodstream infection in a patient with a central line in place >2 calendar days, where the organism is not related to infection at another site.

Central lines that count: non-tunneled CVCs, tunneled catheters (Hickman, Broviac), implanted ports, PICCs, hemodialysis catheters, pulmonary artery catheters. Peripheral IVs and midlines do NOT meet CLABSI criteria.

When to suspect bacteremia:

High-risk hosts: ICU patients, hemodialysis, TPN recipients, hematologic malignancy/neutropenia, bone marrow and solid organ transplant, burns, neonates, IVDU with vascular hardware.

Epidemiology pearls:

Step 3 management: Any febrile patient with a central line gets at least 2 sets of blood cultures BEFORE antibiotics — one peripheral stick and one from each catheter lumen — drawn simultaneously to enable differential time-to-positivity analysis. Empiric antibiotics should not be delayed more than 45 minutes in septic patients while obtaining cultures.

Presentation Patterns and Key History

— Line characteristics: type (tunneled vs non-tunneled, port vs PICC), insertion date, insertion site, number of lumens, indication (TPN, chemo, dialysis, pressors)

— Recent line manipulation: dressing changes, blood draws, infusions, dialysis sessions immediately preceding symptom onset

— Local symptoms: erythema, tenderness, purulence, or induration at exit site or along tunneled tract

— Prior bacteremia or MRSA colonization, recent hospitalizations, recent antibiotic exposure (drives empiric coverage decisions)

— Endovascular hardware: prosthetic valves, pacemakers/ICDs, vascular grafts, joint prostheses — raise threshold for prolonged therapy and metastatic seeding workup

— Rigors within 30 minutes of line flush → tunneled catheter infection until proven otherwise

— Persistent fever despite 48–72 h of appropriate antibiotics → suspect endocarditis, septic thrombophlebitis, retained source, or metastatic abscess

— Fever resolving and recurring with reinfusion through the line → biofilm/luminal source

— TPN → Candida, coagulase-negative staph

— Hemodialysis catheter → S. aureus (high MRSA prevalence)

— Healthcare-exposed/ICU → MDR gram-negatives, Pseudomonas, Enterococcus, Stenotrophomonas

— Lipid emulsions → Malassezia furfur

Classic clinical triad is unreliable — most patients present with fever alone or with nonspecific sepsis features. Absence of fever does not exclude bacteremia, especially in elderly, uremic, cirrhotic, or immunosuppressed patients.

Targeted history elements:

Symptom timing clues:

Organism-suggesting exposures:

Board pearl: A dialysis patient with a tunneled catheter who develops fever and rigors during a hemodialysis run has CLABSI until proven otherwise — draw cultures from the catheter and a peripheral site, start vancomycin empirically, and do not simply pull the catheter without infectious disease and nephrology coordination given access scarcity.

Physical Exam Findings and Hemodynamic Assessment

— Inspect exit site for erythema, induration, purulent drainage, crusting

— Palpate along the subcutaneous tunnel of tunneled catheters for tenderness or fluctuance — tunnel infection mandates removal

— For ports: palpate the pocket for warmth, fluctuance, overlying skin breakdown

— Examine for palpable cord along catheterized vein → septic thrombophlebitis

— Cardiac: new murmur (endocarditis), conduction abnormality on tele (perivalvular abscess)

— Skin: Janeway lesions, Osler nodes, splinter hemorrhages, peripheral septic emboli, ecthyma gangrenosum (Pseudomonas)

— Eyes: dilated funduscopy for endophthalmitis — required in all candidemia within 1 week of diagnosis

— MSK: vertebral tenderness (discitis/osteomyelitis), joint effusions (septic arthritis), psoas signs

— Abdomen: RUQ tenderness (hepatic abscess), splenomegaly

— Neuro: focal deficits (septic emboli, brain abscess), meningismus

— Warm/vasodilated, wide pulse pressure → distributive (classic sepsis)

— Cool, narrow pulse pressure, elevated lactate → consider cardiogenic overlay or under-resuscitation

Vital signs first: assess for SIRS/qSOFA — temperature extremes, HR >90, RR >22, SBP ≤100, AMS. Lactate ≥2 mmol/L or SBP <90 after fluids meets septic shock criteria once vasopressors required.

Catheter site exam (perform on every febrile line patient):

Systemic exam for metastatic foci (mandatory in S. aureus or Candida bacteremia):

Hemodynamic phenotyping:

CCS pearl: On the CCS case, after obtaining vitals and exam, order continuous pulse oximetry, telemetry, two large-bore IVs, and place the patient on NPO if procedure or escalation likely. Examine the line site explicitly — the simulation rewards site-directed assessment and credits "examine catheter exit site" as a discrete action.

Diagnostic Workup — Initial Labs, Cultures, and Imaging

— Obtain ≥2 sets (each set = 1 aerobic + 1 anaerobic bottle, 10 mL/bottle in adults)

— Draw one peripheral venipuncture + one from each catheter lumen simultaneously, label by source

— Differential time to positivity (DTP): catheter culture turning positive ≥2 hours before peripheral culture supports catheter as source (sensitivity ~85%, specificity ~91%)

— Paired quantitative cultures: ≥3-fold higher colony count from catheter vs peripheral also implicates the line

— Repeat cultures every 48–72 h until clearance documented, especially for S. aureus, Candida, gram-negatives

— CBC with differential (neutropenia, bandemia, thrombocytopenia of sepsis/DIC)

— CMP (AKI, hepatic dysfunction)

— Lactate — repeat at 2–4 h if initially elevated

— Coagulation panel and fibrinogen if DIC suspected

— Procalcitonin: not for diagnosis but may guide de-escalation

— UA + urine culture, sputum/wound cultures to exclude alternative sources

— CXR for pulmonary source and to confirm line tip position (carina is target for CVC tip)

— CT abdomen/pelvis if intra-abdominal source suspected or persistent bacteremia

— Duplex ultrasound of the catheterized vein if septic thrombophlebitis suspected (palpable cord, persistent bacteremia despite line removal)

— Maki semiquantitative roll-plate: ≥15 CFU = significant colonization

— Only useful when line is removed; do not remove a line solely to culture the tip

Blood cultures — the cornerstone:

Initial labs:

Imaging:

Catheter tip culture:

Key distinction: A single positive blood culture for coagulase-negative staphylococci in a low-risk patient is usually a contaminant; requires ≥2 positive sets from separate venipunctures to call true bacteremia. S. aureus, S. lugdunensis, gram-negative rods, and Candida are NEVER considered contaminants — single positive culture mandates full workup and treatment.

Diagnostic Workup — Advanced and Confirmatory Studies

— TTE first as screening; sensitivity ~70% for native valve vegetations, lower for prosthetic valves and small vegetations

— TEE indicated when: prosthetic valve, intracardiac device (pacemaker/ICD), persistent bacteremia >72 h, new murmur, embolic phenomena, S. aureus bacteremia with risk factors, or non-diagnostic TTE with high pretest probability

— In uncomplicated S. aureus bacteremia (catheter removed, defervescence ≤72 h, no metastatic foci, no hardware, negative follow-up cultures, normal valves on TTE), TEE may be deferred — but most experts still recommend it

— S. aureus, GNR, Candida → repeat every 48 h until two consecutive negative sets

— Duration of therapy clock starts from the first negative blood culture

— MRI spine for back pain or persistent S. aureus bacteremia → vertebral osteomyelitis/epidural abscess

— CT or MRI brain for any neurologic finding → septic emboli, abscess

— Tagged WBC scan or PET-CT for occult endovascular or prosthetic infection

— Ophthalmology dilated exam mandatory within 1 week of candidemia diagnosis (endophthalmitis in 9–16%)

— MALDI-TOF for rapid organism ID from positive bottles (hours vs days)

— PCR panels (BioFire, Verigene) identify organism and key resistance genes (mecA, vanA, KPC) from positive cultures

— Stewardship pearl: use rapid results to narrow therapy promptly

Echocardiography decisions (critical in S. aureus, enterococcal, streptococcal, and Candida bacteremia):

Follow-up surveillance cultures:

Source-specific imaging:

Molecular and rapid diagnostics:

T2Candida and beta-D-glucan: adjuncts for invasive candidiasis when cultures slow

Board pearl: Persistent bacteremia >72 h on appropriate antibiotics with the line removed should trigger a hunt for complications: endocarditis (TEE), septic thrombophlebitis (venous duplex), endovascular graft infection, vertebral osteomyelitis (MRI), and metastatic abscess (CT). Don't simply extend antibiotics.

Risk Stratification and First-Line Management Logic

1. Is empiric antibiotic coverage adequate and timely?

2. Should the catheter be removed?

3. How long to treat, and what surveillance is needed?

— Lactate, blood cultures BEFORE antibiotics, broad-spectrum antibiotics, 30 mL/kg crystalloid for hypotension or lactate ≥4, vasopressors (norepinephrine first-line) for MAP <65 after fluids

— Severe sepsis or septic shock

— Tunnel infection, port pocket abscess, or septic thrombophlebitis

— Endocarditis or hematogenous metastatic infection

— Persistent bacteremia >72 h despite appropriate antibiotics

— Bacteremia caused by S. aureus, Pseudomonas, fungi (Candida), mycobacteria, or S. lugdunensis

— Long-term catheter (tunneled/port) and limited access alternatives

— Uncomplicated CLABSI with coagulase-negative staph or some enteric GNRs

— No tunnel/pocket infection, no metastatic disease, no hemodynamic instability

— Documented clearance with repeat cultures

— Uncomplicated CoNS: 5–7 days (or 10–14 if line retained)

— S. aureus, uncomplicated: ≥14 days IV from first negative culture

— S. aureus, complicated (endocarditis, metastatic, prosthetic): 4–6 weeks

— Enterococcus, GNR uncomplicated: 7–14 days

— Candida: ≥14 days from first negative culture + remove line + ophtho exam

Three decisions drive management:

Sepsis bundle (within 1 hour of recognition):

Catheter removal — strong indications (remove immediately):

Catheter salvage may be attempted (with antibiotic lock therapy + systemic antibiotics) when:

Duration framework (after first negative culture):

Step 3 management: A hemodynamically stable patient with a tunneled catheter and gram-positive cocci in clusters from one set: do not pull the line yet — repeat cultures, start vancomycin, await speciation. If S. aureus confirmed, pull the line within 24–48 hours. Retention of an S. aureus-infected catheter is associated with markedly higher relapse and mortality.

Pharmacotherapy — Empiric and Targeted Regimens

— Standard empiric: Vancomycin (covers MRSA, CoNS) — load 25–30 mg/kg, then dose by AUC/MIC or trough 15–20

— Add anti-pseudomonal beta-lactam in septic shock, neutropenia, severe burns, or known GNR colonization: cefepime, piperacillin-tazobactam, or meropenem

— Add echinocandin (micafungin 100 mg IV daily) if candidemia risk: TPN, prolonged broad-spectrum antibiotics, GI surgery, hemodialysis, neutropenia, femoral line, severe sepsis without identified source

— Daptomycin (8–10 mg/kg) is an alternative to vancomycin for MRSA bacteremia (NOT for pneumonia — inactivated by surfactant)

— MSSA: Cefazolin (2 g IV q8h) or nafcillin/oxacillin — both superior to vancomycin for MSSA

— MRSA: Vancomycin or daptomycin; ceftaroline for persistent bacteremia

— Enterococcus faecalis: Ampicillin ± ceftriaxone (synergy) or ampicillin + gentamicin

— VRE (E. faecium): Daptomycin or linezolid

— Pseudomonas: Cefepime, pip-tazo, meropenem, or ceftolozane-tazobactam; combination therapy if septic shock

— ESBL Enterobacterales: Meropenem or ertapenem

— CRE: Meropenem-vaborbactam, ceftazidime-avibactam, or cefiderocol per susceptibilities

— Candida albicans/non-albicans: Echinocandin initial; step down to fluconazole if susceptible and stable

Empiric therapy depends on severity, local antibiogram, and host:

Pathogen-directed therapy:

Antibiotic lock therapy (when salvaging line): high-concentration antibiotic (vancomycin 5 mg/mL, gentamicin, ethanol) + heparin instilled in lumen for ≥12 h/day × 10–14 days in addition to systemic therapy

Board pearl: Cefazolin beats vancomycin for MSSA bacteremia — lower mortality and faster clearance. Once susceptibility shows methicillin-sensitive S. aureus, switch from vancomycin to cefazolin even if patient is improving. This is a perennial Step 3 trigger.

Procedures — Line Removal, Replacement, and Source Control

— Hold pressure ≥5 minutes (longer if coagulopathic); position supine to prevent air embolism for upper-body central lines

— Send tip for semiquantitative culture only if infection suspected

— Document hemostasis and absence of complications

— Never use guidewire exchange through an infected site (perpetuates colonization)

— If new access required, place at a new anatomic site after ≥48–72 h of effective antibiotics and ideally documented culture clearance for S. aureus, Pseudomonas, Candida

— For unstable patients needing immediate access: place a new line at a different site

— Septic thrombophlebitis: remove line, anticoagulate (LMWH/heparin) for 4–6 weeks if extensive thrombus or persistent bacteremia, antibiotics 4–6 weeks; surgical excision rarely needed except suppurative peripheral vein

— Tunnel infection or port pocket abscess: I&D + complete hardware removal

— Endocarditis with valve dysfunction, large vegetation >10 mm, embolic events, or perivalvular abscess: cardiac surgery consult for valve replacement

— Endophthalmitis: intravitreal antifungals/antibiotics by ophthalmology

— Tunneled HD catheter infection with uncomplicated CoNS and clinical stability: attempt salvage with antibiotic lock + systemic abx

— S. aureus, Pseudomonas, Candida, or tunnel infection: remove catheter, place temporary non-tunneled HD line at different site, replace tunneled catheter after 72 h of negative cultures

Line removal technique:

When and how to replace:

Site selection hierarchy for infection risk (lowest to highest): subclavian < internal jugular < femoral. Subclavian preferred unless contraindicated (coagulopathy, anatomy).

Source control adjuncts:

Hemodialysis catheter scenarios:

CCS pearl: On a CCS septic shock case with a CVC, order in this sequence — blood cultures (peripheral + catheter), broad-spectrum antibiotics, IV fluids 30 mL/kg, lactate, norepinephrine if MAP <65, then remove the central line and place new access at a different site. The simulation credits explicit "remove central venous catheter" and "insert central venous catheter — new site" as separate actions.

Special Populations — Elderly, Renal, and Hepatic Impairment

— Often afebrile or hypothermic; presentation = delirium, falls, anorexia, generalized weakness

— Lower threshold for cultures with any acute functional decline in line-dependent patient

— Polypharmacy → screen for drug interactions (warfarin + TMP-SMX, statins + linezolid)

— Higher rates of C. difficile after broad-spectrum antibiotics — narrow promptly

— Goals-of-care conversation early; line removal vs salvage influenced by life expectancy and access options

— Vancomycin: dose by AUC; in anuric HD patients, typical regimen is 15–20 mg/kg load then ~500–1000 mg after each HD session (assay-driven)

— Cefepime: dose-adjust to prevent neurotoxicity (encephalopathy, myoclonus, nonconvulsive status) — particularly insidious in CKD

— Daptomycin in HD: dose post-dialysis; monitor CK weekly

— Aminoglycosides: avoid if possible; nephro- and ototoxicity, and unreliable serum levels

— Tunneled HD catheter is the access of last resort — every effort to salvage when feasible because AV fistula/graft creation takes weeks

— Ceftriaxone: avoid in severe cholestasis (biliary sludging); dose-reduce in combined hepatorenal failure

— Linezolid: hepatotoxicity and serotonin syndrome risk with SSRIs

— Tigecycline: black-box warning for increased mortality; avoid bacteremia use unless no alternative

— Cirrhotic SBP-mimicking sepsis can coexist with CLABSI — culture ascites if relevant

— Vancomycin: AUC 400–600, trough 15–20 for serious infection; check renal function every 48 h

— Daptomycin: weekly CK; hold if CK >5× ULN with symptoms or >10× without

— Linezolid: CBC weekly (thrombocytopenia after ~14 days), watch for serotonin syndrome

Elderly:

Renal impairment / hemodialysis:

Hepatic impairment:

Drug-specific monitoring:

Step 3 management: A dialysis patient on vancomycin develops new myoclonus and confusion — check a cefepime level (if on cefepime) and review vancomycin troughs; cefepime neurotoxicity reverses with drug withdrawal and dialysis but is frequently missed.

Special Populations — Pregnancy, Pediatrics, Neutropenia, Immunocompromised

— PICCs commonly used for hyperemesis TPN, IV antibiotics for pyelonephritis

— Safe antibiotics: beta-lactams (penicillins, cephalosporins, carbapenems), vancomycin, daptomycin (limited data, likely safe)

— Avoid: fluoroquinolones (cartilage), tetracyclines (tooth/bone), aminoglycosides (8th nerve in fetus), TMP-SMX in 1st trimester (NTD) and near term (kernicterus), linezolid (limited safety data)

— Sepsis physiology overlaps with normal pregnancy (tachycardia, lower SBP) — use shock index and lactate trends

— Neonatal CLABSI: CoNS most common; consider candidiasis in VLBW

— Weight-based dosing; vancomycin troughs lower target ranges

— Line salvage attempts more common given access scarcity

— Empiric anti-pseudomonal monotherapy: cefepime, pip-tazo, or meropenem

— Add vancomycin if hemodynamic instability, suspected line infection, severe mucositis, prior MRSA, soft tissue/pneumonia

— Add echinocandin for persistent fever >4–7 days on antibacterials

— Filgrastim/pegfilgrastim consideration for high-risk febrile neutropenia

— Do not routinely remove tunneled lines in neutropenic patients with uncomplicated CoNS bacteremia

— Consider Aspergillus, Mucor, Nocardia, CMV viremia mimicking bacteremia

— Tailor empiric coverage to net immunosuppression and post-transplant interval

— Drug interactions: voriconazole + tacrolimus, daptomycin + statins

Pregnancy:

Pediatrics:

Neutropenic patients (ANC <500):

Solid organ and stem cell transplant:

HIV/AIDS: CD4-stratified differential — Bartonella, MAC, Salmonella bacteremia in advanced disease

Board pearl: A neutropenic patient with persistent fever >4 days on broad-spectrum antibiotics needs empiric antifungal coverage (echinocandin or liposomal amphotericin) and a CT chest/sinus/abdomen to hunt for invasive mold disease — pre-emptive therapy reduces mortality.

Complications and Adverse Outcomes

— Highest risk with S. aureus, enterococci, viridans strep, Candida

— Native valve, prosthetic valve (early <12 mo = nosocomial), and device-related (pacemaker leads)

— Complications: heart failure from valve destruction, perivalvular abscess (new AV block), embolic stroke, mycotic aneurysms

— Persistent bacteremia after line removal with venous thrombosis on duplex

— Treat: line removal, antibiotics 4–6 weeks, anticoagulation 4–6 weeks; surgical excision for refractory peripheral cases

— Vertebral osteomyelitis/discitis, epidural abscess (back pain in S. aureus bacteremia = MRI now)

— Septic arthritis (large joints; aspirate before more antibiotics)

— Psoas abscess, hepatic/splenic abscesses

— Renal/perinephric abscess (especially S. aureus)

— Brain abscess, septic pulmonary emboli (right-sided endocarditis)

— Endophthalmitis (Candida — mandatory dilated exam)

— Aortic graft, AV fistula/graft (HD), pacemaker leads, ventricular assist devices — usually require hardware removal for cure

— Same organism within 12 weeks = relapse → search for retained nidus, biofilm, undertreated complication

— Different organism = re-infection → re-evaluate line care and host risk factors

Infective endocarditis:

Septic thrombophlebitis (suppurative thrombophlebitis):

Metastatic seeding:

Septic shock and MODS: mortality 20–50%; ARDS, AKI requiring RRT, DIC, ischemic gut, critical illness myopathy

Endovascular and hardware infections:

Recurrence and relapse:

Long-term sequelae: chronic pain from osteomyelitis, prosthetic valve dependence, AV access loss in HD patients, post-sepsis syndrome (cognitive decline, functional impairment, increased 1-year mortality)

Key distinction: New AV block in a patient with S. aureus or enterococcal bacteremia and known endocarditis = perivalvular abscess until proven otherwise — urgent TEE and cardiothoracic surgery consult; not simply rate-control or pacing.

When to Escalate — ICU, Consultation, and Inpatient Triage

— Septic shock requiring vasopressors

— Respiratory failure (NIV or intubation)

— Lactate ≥4 or persistent ≥2 despite resuscitation

— Major arrhythmia, new AV block, acute decompensated heart failure

— Multi-organ dysfunction (AKI requiring RRT, hepatic failure, DIC)

— Endocarditis with hemodynamic instability or large embolic vegetation

— Hemodynamically stable, afebrile, source controlled, cultures clearing

— Reliable home environment, ability to access labs and infusion services

— Defined endpoint and follow-up plan

— Infectious Diseases: mandatory for S. aureus bacteremia (reduces mortality ~30%); strongly recommended for candidemia, MDR organisms, complicated CLABSI, endocarditis, prosthetic infection

— Cardiology/CT surgery: endocarditis with valvular destruction, large vegetation, perivalvular abscess, embolic complications

— Vascular surgery: suppurative peripheral thrombophlebitis, infected graft

— Interventional radiology: abscess drainage, difficult vascular access

— Nephrology: HD catheter management, AKI requiring RRT

— Ophthalmology: dilated fundus exam for candidemia (within 1 week)

ICU admission criteria:

Step-down/intermediate care: stable but requiring frequent monitoring (q2–4 h vitals), telemetry for embolic risk, complex antibiotic regimens with monitoring

Floor admission: hemodynamically stable bacteremia requiring IV antibiotics, line management, surveillance cultures

Outpatient parenteral antimicrobial therapy (OPAT) candidates:

Consultations:

Step 3 management: Routine ID consultation for S. aureus bacteremia is a quality measure — patients with ID involvement are more likely to receive appropriate echo, source control, correct antibiotic, and adequate duration, with measurable mortality benefit. This is testable as a "what is the next best step?" item.

Key Differentials — Same-Category Bloodstream Infections

— Contaminants typically: CoNS (single set), Cutibacterium (Propionibacterium) acnes, Corynebacterium spp, Bacillus spp, viridans strep (in non-endocarditis contexts)

— Clues to contamination: single positive bottle of multiple drawn, positivity >48–72 h, clinically well patient, organism inconsistent with site

— Always treat as real if: ≥2 sets positive with same organism, S. aureus, S. lugdunensis, GNR, Candida, S. pneumoniae

— Pneumonia → pneumococcal, Klebsiella, S. aureus

— UTI/pyelonephritis → E. coli, Klebsiella, Enterococcus

— Intra-abdominal → polymicrobial GNR + anaerobes

— Skin/soft tissue → S. aureus, beta-hemolytic strep

— Endocarditis → viridans strep, S. aureus, enterococci, HACEK

— Neutropenic oncology patient with GI mucositis and gut organism bacteremia (viridans strep, enterococci, Enterobacterales) → MBI-LCBI, not CLABSI; reporting and root-cause analysis differ

— Transient: dental work, instrumentation, abscess manipulation — usually <30 min, clinically benign in healthy hosts; matters in patients with prosthetic valves

— Sustained: endovascular infection, abscess with continuous seeding

— Catheter-related BSI (CRBSI) = stricter clinical/microbiologic criteria (DTP, paired quantitative, tip culture)

— CLABSI = surveillance definition; broader, used for reporting

True bacteremia vs blood culture contamination:

Primary bacteremia (no source identified) vs secondary bacteremia (identifiable source):

CLABSI vs mucosal barrier injury laboratory-confirmed bloodstream infection (MBI-LCBI):

Transient vs sustained bacteremia:

Catheter-related vs catheter-associated:

Board pearl: A patient with viridans strep bacteremia after dental cleaning who has no prosthetic valve and clears with brief therapy is most often transient; a patient with the same organism, fever for 2 weeks, and a new murmur has subacute endocarditis — TEE and 4–6 weeks of therapy.

Key Differentials — Other-Category Causes of Fever in Line Patients

— Drug fever: beta-lactams, vancomycin, anticonvulsants — eosinophilia, rash, relative bradycardia (Faget sign)

— DVT/PE: catheter-associated upper extremity DVT presents with fever, arm swelling, persistent low-grade temp; duplex US diagnostic

— Transfusion reactions: FNHTR, TRALI, transfusion-transmitted infection

— Postoperative atelectasis (low-grade early POD 1–2 fever)

— Thyroid storm, adrenal crisis in critically ill

— Hematoma resorption (large hematomas at line site)

— Malignancy-related fever: lymphoma, leukemia, renal cell, hepatocellular — diagnosis of exclusion

— Autoimmune/inflammatory: vasculitis, adult-onset Still's, drug-induced lupus

— C. difficile colitis post-broad-spectrum antibiotics — fever, leukocytosis, diarrhea

— Sinusitis from NG/NJ tubes in ICU patients

— Ventilator-associated pneumonia

— Catheter-associated UTI

— Surgical site infection in postoperative patients

— Acalculous cholecystitis in ICU patients on TPN

— Viral syndromes: CMV reactivation in immunocompromised, influenza, COVID-19

— Re-examine line site daily; consider line removal if no alternative source identified after 48–72 h

— Order CT chest/abdomen/pelvis for occult abscess

— Send urine, sputum, stool (C. diff) cultures

— Consider drug fever — stop the most likely offender and observe defervescence (usually within 72 h)

Non-infectious fever mimics in line patients:

Other infectious mimics:

Approach to the line patient with fever and negative blood cultures:

Key distinction: Fever + new upper extremity swelling in a patient with a PICC = upper extremity DVT, possibly septic — order duplex ultrasound of the affected extremity, not just blood cultures. Treatment may include line removal, anticoagulation, and extended antibiotics if septic thrombophlebitis.

Secondary Prevention, Discharge Medications, and Long-Term Plan

— Hand hygiene

— Maximal barrier precautions (cap, mask, sterile gown/gloves, full body drape)

— Chlorhexidine skin antisepsis (allow to dry)

— Optimal site selection (subclavian preferred for non-tunneled CVC in non-HD adults)

— Daily review of line necessity with prompt removal when no longer needed

— Chlorhexidine bathing in ICU patients

— Chlorhexidine-impregnated dressings and/or antimicrobial-impregnated catheters in high-risk units

— Scrub the hub: vigorous 15-second chlorhexidine/alcohol disinfection before every access

— Sterile dressing changes per protocol; replace if soiled, loose, or wet

— Do not routinely replace CVCs to prevent infection (no evidence of benefit)

— Confirmed source control and culture clearance documented

— Defined antibiotic duration and route (often OPAT via PICC — but if PICC was the infected line, consider alternate access)

— Lab monitoring schedule (CBC, BMP, drug levels weekly for prolonged IV therapy)

— Clear endpoint with ID follow-up

— Patient/caregiver education on line care, signs of recurrence (fever, redness, swelling)

— TPN patients: consider ethanol or taurolidine lock therapy for recurrent CLABSI

— Hemodialysis: prioritize AV fistula creation; mupirocin nasal decolonization for S. aureus carriers

— Recurrent S. aureus carriers: mupirocin + chlorhexidine body wash decolonization

Insertion bundle (CLABSI prevention — CMS quality measure):

Maintenance bundle:

Discharge planning after bacteremia/CLABSI:

Secondary prevention specific scenarios:

Endocarditis prophylaxis (post-bacteremia complicated by endocarditis): lifetime prophylaxis before high-risk dental procedures per AHA

CCS pearl: On the CCS discharge screen for a patient completing IV antibiotics for CLABSI, order: outpatient ID follow-up in 1–2 weeks, weekly CBC/CMP and antibiotic levels, home health for line care, and document catheter removal as a completed task. Schedule primary care follow-up within 1 week for medication reconciliation and functional reassessment.

Follow-Up, Monitoring Parameters, and Counseling

— Vital signs q4h until stable; daily exam of catheter site (if retained) or removal site

— Daily CBC, BMP; CRP/procalcitonin trends optional

— Repeat blood cultures every 48 h for S. aureus, GNR, Candida until two consecutive negatives

— Drug monitoring: vancomycin AUC, aminoglycoside peaks/troughs, daptomycin CK, linezolid CBC

— Week 1: PCP or ID — wound check, line site, medication adherence, side effects

— Weekly during OPAT: labs (CBC, BMP, LFTs, drug levels), home health line assessment

— End of therapy: ID visit for cure assessment; consider one set of blood cultures if any clinical concern

— 3 months: reassess for late relapse, especially endocarditis or hardware infection

— Endocarditis: repeat TTE at end of therapy as baseline; earlier if clinical deterioration

— Vertebral osteomyelitis: clinical and ESR/CRP-driven; MRI typically not routinely repeated unless clinical concern

— Reportable symptoms: fever, rigors, line site redness/drainage, new pain at metastatic infection sites

— Avoid submerging line in water (no swimming, baths); cover during showers

— Adhere to scheduled flushes and dressing changes

— Notify all future providers of bacteremia history → endocarditis risk awareness

— Post-sepsis cognitive and functional decline common — consider rehab consult, PT/OT

— Address malnutrition, deconditioning, depression screening at follow-up

— Substance use disorder counseling if IVDU-related (linkage to MAT, harm reduction, addiction medicine)

Acute phase monitoring (inpatient):

Post-discharge follow-up cadence:

Imaging follow-up:

Counseling points:

Functional and rehab considerations:

Step 3 management: A patient completes 6 weeks IV vancomycin for MRSA endocarditis and feels well — schedule end-of-therapy ID visit, repeat TTE for new baseline, blood cultures if any concern, and lifetime AHA endocarditis prophylaxis before high-risk dental procedures. Document this in the discharge summary and primary care record.

Ethical, Legal, and Patient Safety Considerations

— Even in urgent scenarios, document risks (pneumothorax, arterial puncture, infection, thrombosis, air embolism), benefits, alternatives when feasible

— For emergent placement in unconscious patient: implied consent for life-saving access; document urgency and inability to obtain consent

— Use a time-out and procedural checklist — universal protocol applies to bedside line placement

— Retained guidewire is a CMS never event — count and document

— Wrong-site procedure prevention via time-out

— Communicating line presence at every handoff (shift change, transfer to another unit, transfer to another hospital) — use SBAR/I-PASS; document indication and dwell time

— Daily line necessity review documented in progress note

— CLABSI rates reported to NHSN/CDC; tied to CMS value-based purchasing and hospital-acquired condition penalties

— Root cause analysis for sentinel events (e.g., CLABSI-associated death)

— Outbreak reporting to infection prevention and public health

— Patients discharged on OPAT carry significant risk of readmission for line complications, antibiotic toxicity, missed labs — verify functioning infusion pharmacy, transportation, caregiver capacity

— Ensure ID follow-up scheduled before discharge

— Use the narrowest effective agent; de-escalate promptly with susceptibilities

— Avoid empiric vancomycin "just in case" beyond 48–72 h without indication

— Document indication, drug, dose, duration for each antibiotic course

— In recurrent CLABSI in patients with limited prognosis (advanced cancer, end-stage organ failure), discuss whether continued aggressive line-dependent therapy aligns with patient values; palliative care consult appropriate

Informed consent for central line placement:

Patient safety — never events and high-risk transitions:

Mandatory reporting and public reporting:

Transitions of care:

Antimicrobial stewardship ethics:

Goals of care:

Step 3 management: A nursing home patient with advanced dementia and recurrent CLABSI on long-term TPN — initiate goals-of-care conversation with the healthcare proxy, review the advance directive, and consider transition to comfort-focused care or hospice. Continued line-dependent care without clear goals is both ethically and clinically problematic.

High-Yield Associations and Rapid-Fire Clinical Facts

S. aureus bacteremia checklist (memorize): ID consult, TEE, source control (remove line), repeat cultures q48h until clear, ≥14 days IV from first negative culture (uncomplicated), 4–6 weeks if complicated, cefazolin > vancomycin for MSSA.

Candida bacteremia checklist: echinocandin first-line, remove the line always, dilated ophtho exam within 1 week, repeat cultures, TEE if persistent, ≥14 days from first negative culture.

Coagulase-negative staph: single positive set = usually contaminant; ≥2 sets = real; can often salvage line with antibiotic lock + 5–7 days systemic vancomycin.

Subclavian < IJ < femoral for infection risk.

Chlorhexidine beats povidone-iodine for skin antisepsis.

Maki tip culture ≥15 CFU = significant.

Differential time to positivity ≥2 hours (catheter before peripheral) implicates catheter source.

Sepsis bundle: lactate, cultures before antibiotics, broad-spectrum antibiotics within 1 hour, 30 mL/kg crystalloid, norepinephrine for MAP <65.

MRSA risk factors: prior MRSA, hemodialysis, recent hospitalization, nursing home, IVDU, healthcare exposure.

Pseudomonas risk factors: neutropenia, ICU, burns, cystic fibrosis, prior pseudomonal infection, broad-spectrum antibiotic exposure.

HACEK organisms (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella): culture-negative endocarditis cause; ceftriaxone × 4 weeks.

S. lugdunensis: behaves like S. aureus — aggressive, valve destruction, never a contaminant.

Enterococcal bacteremia: screen for GI source (colon cancer in older adults), endocarditis workup.

Cefepime neurotoxicity: myoclonus, encephalopathy, NCSE in renal impairment.

Daptomycin not for pneumonia (surfactant inactivation).

Linezolid: thrombocytopenia, serotonin syndrome, optic neuropathy with prolonged use.

Ethanol locks: prevent recurrent TPN-related CLABSI.

Board pearl: Persistent S. aureus bacteremia >72 h on appropriate vancomycin: check MIC (vancomycin MIC creep ≥2), consider switching to daptomycin (8–10 mg/kg) ± ceftaroline, and aggressively hunt for undrained source — TEE, MRI spine, CT chest/abdomen.

Board Question Stem Patterns

Pattern 1 — "Best next step": Febrile ICU patient with a CVC, hemodynamically unstable → next step is two sets of blood cultures (peripheral + catheter) and empiric broad-spectrum antibiotics within 1 hour (vancomycin + cefepime/pip-tazo). Don't pick "remove the line" without first culturing.

Pattern 2 — "MSSA on susceptibilities": Patient improving on vancomycin for S. aureus bacteremia; culture returns methicillin-sensitive → switch to cefazolin or nafcillin. Trap answer: continue vancomycin because patient is improving.

Pattern 3 — Candidemia next step: Patient with TPN and candidemia → start echinocandin (micafungin), remove the central line, order dilated ophthalmologic exam, repeat cultures q48h. Treat ≥14 days from first negative culture.

Pattern 4 — Contaminant vs real: Asymptomatic patient, 1 of 4 bottles grows CoNS → most likely contaminant; observe, repeat cultures only if symptomatic. Avoid empiric vancomycin.

Pattern 5 — Persistent bacteremia: S. aureus bacteremia, line removed, on vancomycin × 5 days, still febrile, cultures still positive → TEE + MRI spine + CT chest/abdomen to find occult source; reassess antibiotic choice/MIC.

Pattern 6 — Tunnel infection: Tunneled HD catheter with erythema extending along subcutaneous tract + bacteremia → remove the catheter (cannot salvage); place temporary HD line at different site.

Pattern 7 — Hemodialysis CLABSI with CoNS: Stable patient, no tunnel infection, no metastatic disease → antibiotic lock + systemic vancomycin × 10–14 days, attempt salvage to preserve access.

Pattern 8 — Septic thrombophlebitis: Persistent bacteremia despite line removal + appropriate antibiotics → venous duplex showing thrombus → anticoagulate, extend antibiotics 4–6 weeks.

Pattern 9 — Neutropenic fever + line: ANC <500, fever, CVC in place → cefepime monotherapy; add vancomycin only for specific indications; add echinocandin if fever persists ≥4–7 days.

Pattern 10 — Prevention question: Lowest infection risk site = subclavian. Best skin antiseptic = chlorhexidine-alcohol. Best timing for line removal = as soon as no longer needed (daily review).

CCS pearl: Septic shock from CLABSI CCS case sequence: ABCs → 2 large-bore IVs → blood cultures (peripheral + catheter) → vancomycin + cefepime → IV crystalloid 30 mL/kg → lactate → norepinephrine if MAP <65 → remove CVC, replace at new site → ICU transfer → ID consult → daily progress notes documenting cultures and antibiotic adjustments.

One-Line Recap

Bacteremia in a patient with a central venous catheter is CLABSI until proven otherwise — draw paired blood cultures, start empiric vancomycin (± anti-pseudomonal beta-lactam ± echinocandin per host), remove the line for S. aureus/Pseudomonas/Candida/tunnel infection/septic shock/persistent bacteremia, treat ≥14 days IV from first negative culture (longer if complicated), and consult Infectious Diseases for every S. aureus or Candida bloodstream infection.

Diagnostic core: ≥2 sets of cultures (peripheral + catheter); differential time-to-positivity ≥2 hours or paired quantitative ≥3:1 implicates the line; never consider S. aureus, S. lugdunensis, GNR, or Candida a contaminant.

Treatment core: Empiric vancomycin; cefazolin/nafcillin for MSSA (better than vancomycin); echinocandin for Candida; duration measured from first negative culture; repeat cultures q48h until clear for S. aureus, GNR, Candida.

Source control core: Remove the line for S. aureus, Pseudomonas, Candida, mycobacteria, S. lugdunensis, tunnel/pocket infection, septic shock, endocarditis, suppurative thrombophlebitis, or persistent bacteremia >72 h; never replace over a guidewire through an infected site.

Complications core: Always evaluate for endocarditis (TEE), vertebral osteomyelitis (MRI), septic thrombophlebitis (venous duplex), endophthalmitis (dilated exam for Candida), and metastatic abscess (CT) when bacteremia persists or organism is high-risk.

Prevention core: Subclavian > IJ > femoral; chlorhexidine antisepsis; maximal barrier precautions; daily necessity review with prompt removal; scrub the hub; CMS value-based reporting metric.

Step 3 management: ID consultation for every S. aureus bacteremia is a mortality-reducing quality measure and a recurring "next best step" answer.